Infections that were once easily treatable are now becoming dangerous and even fatal due to bacteria and other microbes developing resistance to the drugs designed to kill them. Novo Holdings is committed to addressing antimicrobial resistance (AMR) through initiatives such as our REPAIR Impact Fund and our investment in the AMR Action Fund. Novo Holdings Partner Aleks Engel provides an update on some of our activities in this space. #antimicrobialresistance
Novo Holdings
Finansielle tjenesteydelser
Hellerup, Gentofte 50.700 følgere
Investing to benefit people and the planet
Om os
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, one of the world’s largest philanthropic enterprise foundations. Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S and manages an investment portfolio, with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.
- Websted
-
http://www.novoholdings.dk
Eksternt link til Novo Holdings
- Branche
- Finansielle tjenesteydelser
- Virksomhedsstørrelse
- 51-200 medarbejdere
- Hovedkvarter
- Hellerup, Gentofte
- Type
- Privat
- Grundlagt
- 1999
- Specialer
- Seed Financing, Venture Capital, Large Investments og Financial Management
Beliggenheder
-
Primær
Novo Holdings A/S
Tuborg Havnevej 19
Hellerup, Gentofte 2900, DK
Medarbejdere hos Novo Holdings
-
Camilla Soenderby
Biopharma C-suite Executive & Board Director┃ International P&L Management┃ Global Portfolio & Product Strategy, Commercialisation and Life Cycle…
-
Ian Laquian
-
Britt Meelby Jensen
-
Karl Hess
From bench to bedside to banker: Digital health & HealthTech CEO / ecosystem builder turned investment banker.
Opdateringer
-
Our team in China recently moved to new offices in the Jing’an District, located in downtown Shanghai. To mark the occasion, we were delighted to have the company of friends, business partners, and portfolio companies who joined us at our new space for a networking reception. We were specially honoured to have Ambassador Mikael H. Winther, Consul General of Denmark to Shanghai, grace the event and share his rich insights with our guests. Since establishing a presence in China in 2022, we have focused on sectors with solid long-term fundamentals driven primarily by domestic growth opportunities in the areas of life science tools, MedTech, pharma services, and planetary health. We are grateful to our portfolio companies, business partners, and advisors for the continued partnership and collaboration as we continue investing with a mission of improving people’s health and sustainability of the planet. Denmark in China #lifesciences #medtech #pharmaservices #planetaryhealth #China
-
-
-
-
-
+ 1
-
-
We are looking for a Junior Analyst to support our activities in our Accounting team. It is a part-time student job, and your daily tasks and responsibilities will mainly be bookkeeping, reimbursement of expenses and monitoring and maintenance of accounts payables and accounts receivables as well as preparation of bank reconciliations, month-end closing processes and various ad hoc tasks.
Junior Analyst (student), Finance & Operations - Novo Holdings
apply.workable.com
-
CEO Kasim Kutay spoke with Bloomberg’s Francine Lacqua this morning on AI in healthcare, preventative models of care, the clinical trial landscape and GreenTech.
In Full: Novo Holdings CEO on Green Investing, NHS, AI
bloomberg.com
-
Novo Holdings announces a £50 million investment in Oxford Nanopore Technologies by our Growth Equity team. Oxford Nanopore has developed a new generation of sensing technology, providing DNA/RNA sequencing information using a range of devices from the pocket size to ultra-high output devices. The technology is used to understand and answer questions about human biology as well as plant, animal, pathogen and planetary health. One emerging use is in biopharma, where rapid, direct RNA sequencing can enable biological manufacturing and quality control processes for an emerging class of mRNA-based products.
Novo Holdings Invests in UK-Listed Oxford Nanopore Technologies
novoholdings.dk
-
Novo Holdings led a $105 million financing of Magenta Medical, the developer of the Elevate System, a proprietary technology behind the world’s smallest heart pump. Proceeds from the financing will be used to advance Magenta Medical’s US clinical programs in multiple mechanical circulatory support indications, and to secure US FDA approval for Magenta’s Elevate™ System in patients undergoing high-risk percutaneous coronary interventions. Learn more about Magenta and the need for mechanical circulatory support devices below. #ventureinvestments #medtech
Novo Holdings leads $105 million financing of Magenta Medical to support FDA approval for world’s smallest heart pump
novoholdings.dk
-
Today Novo Holdings portfolio company Invetx announced an agreement to be acquired by Dechra Pharmaceuticals, an international veterinary pharmaceuticals company, for up to $520 million. Novo Holdings co-led Invetx’s Series B financing in 2022, which enabled Invetx to advance its clinical pipeline and pursue market approvals for innovative, protein-based therapeutics targeting chronic and serious diseases in animals. Novo Holdings is pleased to have supported Invetx in its ongoing journey to transform animal medicine and pioneer the next generation of veterinary care. Learn more about Invetx and this announcement below.
Novo Holdings Portfolio Company Invetx to be Acquired by Dechra Pharmaceuticals
novoholdings.dk
-
Novo Holdings led a $100 million Series C Financing in Asceneuron, a clinical stage biotech company developing small molecules targeting tau protein aggregation, a driver of neurodegenerative disease. The financing will be used to advance Asceneuron’s lead asset ASN51 into Phase 2 clinical development for the treatment of Alzheimer’s disease. Alzheimer’s disease is an area of very high unmet medical need with a lack of oral disease modifying therapies. Learn more about Asceneuron and the science behind this therapy below. #ventureinvestments #alzheimers
Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer’s disease
novoholdings.dk
-
We are looking for a Junior Analyst to support our activities in our Investment Operations Team. It is a part-time student job, and the role will primarily support our internal procedures, but also on our cash and liquidity management, as well as being an operational support for our investment teams both in private and public trading.
Junior Analyst (student) for Novo Holdings Investment Operations Team - Novo Holdings
apply.workable.com